Propionibacterium Acnes in Shoulder Arthroplasty
Launched by UNIVERSITY OF UTAH · Feb 15, 2017
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
Over half of all post-operative infections after shoulder arthroplasty are due to Propionibacterium acnes. Even in apparently "aseptic" revisions, nearly all cultures taken at the time of revision surgery are positive for P acnes, and thus low-grade infection with this bacteria may be a more common cause of failure than previously suspected. Current antibiotic prophylaxis methods are ineffective against P acnes. Despite intravenous cefazolin, P acnes can be cultured from the glenohumeral joint in 42% of patients undergoing primary total shoulder arthroplasty. Despite skin preparation with c...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing primary shoulder arthroplasty
- Exclusion Criteria:
- • Patients with prior shoulder surgery.
- • Patients with a symptomatic infection or history of infection, recent antibiotic use (within six weeks), or with clinical signs of infection such as an elevated ESR, CRP, positive aspiration cultures, or positive biopsy.
- • Patients with a known hypersensitivity to hydrogen peroxide.
About University Of Utah
The University of Utah is a prestigious research institution known for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. With a robust infrastructure that supports a wide range of biomedical research initiatives, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies. By fostering collaboration among researchers, clinicians, and community partners, the University of Utah aims to translate scientific discoveries into effective therapies and interventions, ultimately enhancing health outcomes and contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salt Lake City, Utah, United States
Patients applied
Trial Officials
Peter Chalmers, MD
Principal Investigator
University of Utah
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials